ORR, PFS, and OS in the entire patient cohort in patients with different characteristics
| Patients . | No. of patients . | ≥VGPR (%)* . | ORR (%)* . | Median PFS (mo) . | Median OS (mo) . |
|---|---|---|---|---|---|
| All patients | 79 | 35.4 | 60.8 | 9.7 | 25.6 |
| FISH high-risk | 30 | 36.7 | 53.0 | 9.3 | 22.8 |
| FISH standard-risk | 39 | 35.9 | 67.0 | 11.1 | N/R |
| Pretreatment with bortezomib | 50 | 28.0 | 56.0 | 8.6 | 25.6 |
| None | 29 | 48.3 | 69.0 | 12.4 | N/R |
| 1 line | 42 | 28.6 | 54.8 | 8.6 | 25.6 |
| 2-3 lines | 8 | 25.0 | 62.5 | 4.4 | 9.8 |
| Pretreatment with lenalidomide | 42 | 26.2 | 55.0 | 8.3 | 20.6 |
| None | 37 | 45.9 | 67.6 | 12.3 | N/R |
| 1 line | 33 | 33.3 | 57.6 | 8.5 | 21.6 |
| 2-3 lines | 9 | 0.0 | 44.4 | 5.4 | 13.5 |
| Pretreatment with lenalidomide and bortezomib | 32 | 18.8 | 46.9 | 7.1 | 17.4 |
| Pretreatment with neither lenalidomide nor bortezomib | 19 | 47.4 | 63.2 | 12.0 | N/R |
| No. of prior treatment lines | |||||
| 1-2 | 50 | 42.0 | 66.0 | 12.0 | N/R |
| 3-6 | 29 | 24.1 | 51.7 | 7.8 | 19.9 |
| Relapse status at start of BBD | |||||
| Relapsing to the preceding treatment line* | 58 | 36.2 | 63.8 | 11.1 | 27.3 |
| Refractory to the preceding treatment line* | 21 | 28.6 | 52.4 | 8.0 | 23.7 |
| Patients . | No. of patients . | ≥VGPR (%)* . | ORR (%)* . | Median PFS (mo) . | Median OS (mo) . |
|---|---|---|---|---|---|
| All patients | 79 | 35.4 | 60.8 | 9.7 | 25.6 |
| FISH high-risk | 30 | 36.7 | 53.0 | 9.3 | 22.8 |
| FISH standard-risk | 39 | 35.9 | 67.0 | 11.1 | N/R |
| Pretreatment with bortezomib | 50 | 28.0 | 56.0 | 8.6 | 25.6 |
| None | 29 | 48.3 | 69.0 | 12.4 | N/R |
| 1 line | 42 | 28.6 | 54.8 | 8.6 | 25.6 |
| 2-3 lines | 8 | 25.0 | 62.5 | 4.4 | 9.8 |
| Pretreatment with lenalidomide | 42 | 26.2 | 55.0 | 8.3 | 20.6 |
| None | 37 | 45.9 | 67.6 | 12.3 | N/R |
| 1 line | 33 | 33.3 | 57.6 | 8.5 | 21.6 |
| 2-3 lines | 9 | 0.0 | 44.4 | 5.4 | 13.5 |
| Pretreatment with lenalidomide and bortezomib | 32 | 18.8 | 46.9 | 7.1 | 17.4 |
| Pretreatment with neither lenalidomide nor bortezomib | 19 | 47.4 | 63.2 | 12.0 | N/R |
| No. of prior treatment lines | |||||
| 1-2 | 50 | 42.0 | 66.0 | 12.0 | N/R |
| 3-6 | 29 | 24.1 | 51.7 | 7.8 | 19.9 |
| Relapse status at start of BBD | |||||
| Relapsing to the preceding treatment line* | 58 | 36.2 | 63.8 | 11.1 | 27.3 |
| Refractory to the preceding treatment line* | 21 | 28.6 | 52.4 | 8.0 | 23.7 |